Physician profile
Emma Rubin
NPI 1902965924
$7,644.55
in general payments reported to CMS, 2019-2025
45 companies · $917 in 2025
The $917 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,787 · 2020: $421 · 2021: $922 · 2022: $1,202 · 2023: $1,332 · 2024: $1,064 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,312.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,074.93 | 2019-2025 | Xifaxan, Relistor |
| Glaxosmithkline, LLC. | $976.23 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $724.38 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Janssen Biotech, INC. | $596.79 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $472.02 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $385.00 | 2019-2025 | Entyvio |
| Novo Nordisk INC | $356.22 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $338.70 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Qol Medical, LLC | $297.77 | 2022-2025 | Sucraid, Sucraid |
| Astrazeneca Pharmaceuticals LP | $196.66 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $166.41 | 2021-2023 | |
| Gilead Sciences, INC. | $161.68 | 2019-2021 | |
| Abbott Laboratories | $144.99 | 2021-2023 | Freestyle Libre 3 |
| Shield Therapeutics INC | $127.83 | 2023-2024 | Accrufer |
| Amgen INC. | $126.35 | 2019-2023 | Otezla, Repatha |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.